Last but not least, as both obesity and NAFLD may lead to the development of HCC, and in the absence of any approved medication specifically for NAFLD, it should be evaluated whether targeting obesity may prevent NAFLD-associated HCC, by affecting adiponectin and/or TNF-α production. The gene discussed is ADIPOQ; the disease is metabolic dysfunction-associated steatotic liver disease.